rs1058322 — ADIPOR2

ADIPOR2 rs1058322: Reduced Receptor Expression, Cardiovascular Risk, and the Adiponectin Signaling Gap

Adiponectin is a fat-tissue hormone with a counterintuitive property: its levels fall as body fat increases, precisely when its metabolic protection is most needed. Low circulating adiponectin is a consistent predictor of insulin resistance, type 2 diabetes, dyslipidaemia, and cardiovascular disease¹¹ Low circulating adiponectin is a consistent predictor of insulin resistance, type 2 diabetes, dyslipidaemia, and cardiovascular disease
Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26:439–451. The metabolic effects of adiponectin depend entirely on two transmembrane receptors: ADIPOR1, which is dominant in skeletal muscle, and ADIPOR2, which is dominant in the liver. rs1058322 is an intronic variant in ADIPOR2 — it does not change the receptor's amino acid sequence, but carriers of the T allele show measurably lower ADIPOR2 mRNA expression in circulating immune cells, suggesting the variant influences gene expression through altered splicing or regulatory context.

The Mechanism

When adiponectin binds ADIPOR2 in the liver, two downstream pathways activate: the AMPK pathway²² AMPK pathway
AMP-activated protein kinase — a master metabolic sensor that shifts cells toward catabolism, increasing fatty acid oxidation and glucose uptake while suppressing hepatic fat synthesis and gluconeogenesis and the PPARα pathway³³ PPARα pathway
Peroxisome proliferator-activated receptor alpha — a nuclear receptor that transcribes genes for hepatic fatty acid oxidation and lipid export; ADIPOR2 is its primary activator in liver. Together, these reduce hepatic fat accumulation, improve insulin sensitivity, lower LDL, and suppress inflammatory lipid species. The T allele at rs1058322 appears to reduce ADIPOR2 expression, leaving fewer functional receptor molecules at the hepatocyte membrane — the adiponectin signal arrives but finds fewer docking stations, blunting both AMPK and PPARα activation. The net result is a liver that is measurably less responsive to adiponectin's metabolic protection.

The Evidence

The primary evidence comes from the Finnish Diabetes Prevention Study (DPS)⁴⁴ Finnish Diabetes Prevention Study (DPS)
A randomized lifestyle intervention trial in Finland enrolling individuals with impaired glucose tolerance (IGT); 484 participants were genotyped for ADIPOR2 variants and followed for a median of 10.2 years for cardiovascular events. The rs1058322 T allele was dose-dependently associated with higher CVD risk: the additive model showed HR 1.601 (95% CI 1.021–2.509, p = 0.040) and the dominant model HR 1.711 (95% CI 1.114–2.627, p = 0.014). When rs1058322 was tested alongside three other ADIPOR2 variants in a joint multi-SNP model, it remained a significant independent predictor (p = 0.020), indicating unique risk information not redundant with other ADIPOR2 loci (r² = 0.094 with rs11061937).

The expression data that mechanistically links the variant to risk comes from the Genobin sub-study within the DPS analysis (n = 56)⁵⁵ Genobin sub-study within the DPS analysis (n = 56)
A Finnish metabolic cohort used to validate expression phenotypes discovered in the DPS genetic analysis; Siitonen et al. Cardiovasc Diabetol, 2011. Carriers of the T allele showed significantly lower ADIPOR2 mRNA levels in peripheral blood mononuclear cells compared with CC homozygotes (p = 0.029), providing a biological mechanism: T allele → reduced receptor expression → blunted adiponectin signaling → elevated cardiometabolic risk.

The broader biology is supported by receptor-disruption experiments: AdipoR1 and AdipoR2 knockout mice show opposing metabolic effects, confirming the receptors have distinct non-redundant roles in energy metabolism⁶⁶ AdipoR1 and AdipoR2 knockout mice show opposing metabolic effects, confirming the receptors have distinct non-redundant roles in energy metabolism
Bjursell M et al. Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. Diabetes, 2007. Synthetic ADIPOR agonists that activate both receptors reduce insulin resistance and extend lifespan in obese diabetic mice⁷⁷ reduce insulin resistance and extend lifespan in obese diabetic mice
Okada-Iwabu et al. AdipoRon improves obesity-related metabolic disease. Nature, 2013, validating the pathway as therapeutically relevant and confirming that augmenting receptor signaling can meaningfully offset metabolic risk.

Practical Actions

The actionable targets for this variant are strategies that raise circulating adiponectin concentration — increasing the ligand supply to partially compensate for reduced receptor density — and that support hepatic fatty acid oxidation and AMPK activation independently. Omega-3 fatty acids (EPA and DHA) raise serum adiponectin in intervention studies and are the most directly relevant dietary lever. Replacing saturated fat with polyunsaturated sources raises adiponectin by 10–15% in dietary intervention trials. Given the CVD signal from the Finnish DPS, cardiometabolic monitoring is appropriate for T allele carriers, particularly those with additional risk factors such as impaired fasting glucose, elevated triglycerides, or a family history of cardiovascular disease.

Interactions

rs1058322 was co-analyzed with rs11061937, rs10848554, and rs16928751 in the Finnish DPS; all four SNPs showed nominal CVD associations and rs1058322 maintained independent significance alongside rs11061937 in the multi-SNP model. These variants tag distinct positions across the ADIPOR2 locus and may collectively describe a haplotype with compounded effects on receptor expression or function. Individuals carrying T alleles at rs1058322 alongside risk alleles at rs11061937 may have a more substantially reduced hepatic adiponectin response than either variant alone predicts. The interaction warrants a compound action (see harvesting notes below).